PDE3A-SLFN12 Molecular Glues Target Multiple KIT D816V Cell Types in Preclinical Models of Mast Cell Malignancies

Abstract excerpt

A drug discovery approach was used to specifically target malignant cells with KIT D816V mutation, which is the predominant disease-causing mutation in clonal mast cell malignancies. To this end, KIT D816V cells derived from induced pluripotent stem cells (iPS cells) of KIT D816V patients were employed to screen a library of FDA approved and experimental drugs for specific killing of KIT D816V cells. We discovered...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Agents
• Cyclic Nucleotide Phosphodiesterases, Type 3
• Mastocytosis, Systemic
• Models, Biological
• Mutation
• Nerve Growth Factors
• Proto-Oncogene Proteins c-kit
• Xenograft Model Antitumor Assays

Identifiers and source

Literature Corpus work

e2ac2ba1-6914-5a58-9b30-ccfaa7129368

DOI

10.64898/2026.08.13.744624